Pioglitazone — NZ Medication Guide
📋 Reviewed by a Registered Pharmacist NZ — This information is for general educational purposes only and does not replace professional medical advice. Always consult your doctor or pharmacist before starting, stopping, or changing any medication.
What is Pioglitazone?
Pioglitazone is a thiazolidinedione (TZD) insulin sensitiser used for the management of type 2 diabetes mellitus. This medication is funded by Pharmac under Special Authority for type 2 diabetes in combination therapy.
What is Pioglitazone Used For?
Pioglitazone is used for type 2 diabetes, either alone or in combination with metformin, sulfonylureas, or insulin, to improve glycaemic control through insulin sensitisation.
How Does Pioglitazone Work?
Pioglitazone is a PPAR-gamma agonist that activates peroxisome proliferator-activated receptor gamma, a nuclear receptor that regulates genes involved in glucose and lipid metabolism. This increases insulin sensitivity in peripheral tissues (muscle, fat), reduces hepatic glucose output, and improves lipid profile.
How to Take Pioglitazone
Taken once daily, with or without food. Starting dose is 15–30 mg/day, with a maximum of 45 mg/day. Effects on HbA1c develop over 2–3 months. Monitor for fluid retention and weight changes.
Common Side Effects of Pioglitazone
- Weight gain
- Fluid retention and ankle oedema
- Upper respiratory tract infections
- Headache
- Dizziness
Serious Side Effects — Seek Medical Attention
Contact your doctor or call 111 immediately if you experience any of the following:
- Heart failure (contraindicated in NYHA class III and IV heart failure — fluid retention can precipitate or worsen heart failure)
- Bladder cancer (rare — increased risk with long-term high-dose use)
- Osteoporosis and fractures (particularly in women — increases peripheral fracture risk)
- Macular oedema (report any visual changes)
- Severe hepatotoxicity (rare)
Drug Interactions
Pioglitazone may interact with other medicines. Always inform your doctor and pharmacist of all medications you are taking. Key interactions include:
- Insulin (increased hypoglycaemia risk — may need to reduce insulin dose)
- CYP2C8 inhibitors (gemfibrozil — markedly increase pioglitazone levels)
- CYP2C8 inducers (rifampicin — reduce pioglitazone levels)
New Zealand Prescribing Information
Pioglitazone (15 mg, 30 mg, 45 mg tablets — Actos® and generics) is funded by Pharmac under Special Authority for type 2 diabetes. It is contraindicated in heart failure and should be used with caution in patients at risk of fractures, bladder cancer (avoid in patients with a history of bladder cancer), or macular oedema.
Frequently Asked Questions
Does pioglitazone cause weight gain?
Yes — fluid retention and increased fat redistribution cause weight gain in most patients. This can worsen heart failure. Monitor for rapid weight gain (more than 1–2 kg in a week), ankle swelling, and breathlessness.
What is the bladder cancer risk with pioglitazone?
Long-term use (>1 year) at higher doses has been associated with a small increased risk of bladder cancer. While the absolute risk is low, pioglitazone is contraindicated in patients with a history of bladder cancer, and any blood in the urine during treatment should be reported promptly.
⚠️ Disclaimer: This page is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or a qualified health provider. In New Zealand, medication availability and funding may vary — check with Pharmac or your pharmacist for current information.
Reviewed by a Registered Pharmacist NZ
References & Further Information
The following New Zealand and international resources were used to inform this page: